

Adjuvant Therapies of Cancer

Edited by

G. Mathé G. Bonadonna S. Salmon

Adjuvant Therapies of Cancer

Edited by

G. Mathé G. Bonadonna S. Salmon

With 108 Figures and 146 Tables



Springer-Verlag
Berlin Heidelberg New York 1982

Prof. G. Mathé
Institut de Cancérologie et d'Immunogénétique
Hôpital Paul-Brousse, 14-16 Avenue Paul-Vaillant-Couturier
F-94800 Villejuif

Dr. G. Bonadonna
Istituto Nazionale per lo Studio e la Cura dei Tumori
Via Venezian 1, I-20133 Milan

Prof. S. Salmon
The University of Arizona, Health Science Center
Department of Internal Medicine
Section of Hematology and Oncology
Tucson, AZ 85724 (USA)

Sponsored by the Swiss League against Cancer

ISBN 3-540-10949-8 Springer-Verlag Berlin Heidelberg New York
ISBN 0-387-10949-8 Springer-Verlag New York Heidelberg Berlin

Library of Congress Cataloging in Publication Data. Main entry under title: Adjuvant therapies of cancer. (Recent results in cancer research; 80) Bibliography: p. Includes index. I. Cancer—Treatment. I. Mathé, Georges, 1922. II. Bonadonna, G., 1934. III. Salmon, S. E. (Sydney E.). 1936. IV. Series. [DNLM: 1. Adjuvants, Immunologic—Therapeutic use. 2. Adjuvants, Pharmaceutic—Therapeutic use. 3. Neoplasms—Drug therapy. W1 RE106P v. 80/QZ 267 A235] RC261.R35 vol. 80 [RC270.8] 616.99'4s 81-9289 [616.99'406] AACR2.

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically those of translation, reprinting, re-use of illustrations, broadcasting, reproduction by photocopying machine or similar means, and storage in data banks. Under § 54 of the German Copyright Law where copies are made for other than private use a fee is payable to 'Verwertungsgesellschaft Wort', Munich.

© Springer-Verlag Berlin Heidelberg 1982
Printed in Germany

The use of registered names, trademarks, etc. in the publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Typesetting and printing: Carl Ritter GmbH & Co. KG, Wiesbaden
Binding: J. Schäffer OHG, Grünstadt

2125/3140-543210

List of Senior Authors

R. W. Baldwin
Cancer Research Campaign Laboratories, Nottingham,
United Kingdom

J. G. Bekesi
The Mount Sinai School of Medicine and Hospital,
New York, NY, USA

G. Beretta
Ospedale San Carlo, Milan, Italy

M. Betzler
Universität Ulm, Ulm, Germany

G. Bonadonna
Istituto Nazionale Tumori, Milan, Italy

A. Brugarolas
Hospital General de Asturias, Oviedo, Spain

D. Chassagne
Institut Gustave-Roussy, Villejuif, France

B. M. Czarnetzki
Dermatologische Klinik, Münster, Germany

R. Favre
Institut J. Paoli, I. Calmettes, Marseille, France

M. Gasparini
Istituto Nazionale Tumori, Milan, Italy

C. Gisselbrecht
Hôpital Saint-Louis, Paris, France

A. Goldin
National Cancer Institute, NIH, Bethesda, MD, USA

A. Goldman
Royal Marsden Hospital, London, United Kingdom

S. Gore

MRC Biostatistics Unit, Medical Research Council Center,
Cambridge, United Kingdom

P.N. Grozea

Oklahoma Medical Research Foundation, Oklahoma City, OK,
USA

B. Hoerni

Foundation Bergonié, Bordeaux, France

D.K. Hossfeld

Medizinische Universitätsklinik, Essen, Germany

L. Israel

Hôpital Avicenne, Bobigny, France

C. Jacquillat

Institut de Recherches sur les Mélanomes Malins,
Lariboisière Saint-Louis, Paris, France

C. Jasmin

Hôpital Paul-Brousse, Villejuif, France

S.E. Jones

Arizona Health Sciences Center, Tucson, AZ, USA

D.L. Kisner

National Cancer Institute, Bethesda, MD, USA

F. Lacour

Institut Gustave-Roussy, Villejuif, France

M. Lethinen

Tampere Central Hospital, Tampere, Finland

B.P. Le Mevel

Centre René Gauducheau, Nantes, France

H.P. Lohrmann

Universität Ulm, Ulm, Germany

J.S. Macdonald

National Cancer Institute, Bethesda, MD, USA

G. Mathé

Hôpital Paul-Brousse, Villejuif, France

C. Maver

Albany Medical College, Albany, NY, USA

J.L. Misset

Hôpital Paul-Brousse, Villejuif, France

A.M. Neville

Ludwig Institute for Cancer Research, Sutton, Surrey,
United Kingdom

R. Nissen-Meyer
Oslo, Norway

L. Olsson
Hôpital Paul-Brousse, Villejuif, France

J. Y. Petit
Institut Gustave-Roussy, Villejuif, France

J. W. Reid
Naval Regional Medical Center, Portsmouth, VA, USA

P. Reizenstein
Karolinska Hospital, Stockholm, Sweden

S. E. Salmon
University of Arizona, Health Sciences Center, Tucson, AZ,
USA

P. Schlag
Universität Ulm, Ulm, Germany

C. G. Schmidt
Innere Universitätsklinik und Poliklinik, Essen, Germany

H. J. Senn
Kantonsspital, St. Gallen, Switzerland

B. Serrou
Hôpital Saint-Eloi, Montpellier, France

J. C. Sharp
King's College Hospital, London, United Kingdom

F. Spreafico
Istituto di Ricerche Farmacologiche 'Mario Negri', Milan,
Italy

T. H. M. Stewart
University of Ottawa, Ottawa, Ontario, Canada

R. Storb
Fred Hutchinson Cancer Research Center, Seattle, WA, USA

H. Strander
Karolinska Hospital, Stockholm, Sweden

T. Tursz
Institut Gustave-Roussy, Villejuif, France

P. Valagussa
Istituto Nazionale Tumori, Milan, Italy

E. van der Schueren
Academisch Ziekenhuis St. Rafael, Leuven, Belgium

F. Volterrani
Istituto Nazionale Tumori, Milan, Italy

M. Weil

Institut de Recherches sur les Maladies du Sang,
Hôpital Saint-Louis, Paris, France

B. Weiss

National Cancer Institute, Bethesda, MD, USA

J.M.A. Whitehouse

CRC and Wessex Regional Medical Oncology Unit,
Southampton, United Kingdom

Contents

I. General Considerations	1
1. Metastatic Potential of Metastases, Tumor Cell Heterogeneity, and Therapeutic Implications (F. Spreafico, A. Mantovani, R. Giavazzi, G. Conti, and A. Anaclerio)	1
2. Immune Imbalance and Immune Modulation in Solid Tumor Patients: New Insights (B. Serrou, D. Cupissol, and C. Rosenfeld)	9
3. Markers of Minimal Residual Disease (A. M. Neville)	17
4. Radiotherapy as Adjuvant Local Therapy of Local Tumors (D. Chassagne)	22
 II. Hemopoietic and Lymphoid Neoplasias	26
5. Comparison of HLA Phenotypes in Long-Term Survivors with Acute Lymphoblastic Leukemia Treated with Immunotherapy Versus Chemotherapy (T. Tursz, J. Hors, M. Lipinski, J.-L. Amiel, and G. Mathé)	26
6. An Intensive Chemo- or Chemoimmunotherapy Regimen for Patients with Intermediate and Poor-Prognosis Acute Lymphatic Leukemia and Leukemic Lymphoblastic Lymphosarcoma: Preliminary Results with 14-Month Median Follow-Up (J. L. Misset, F. De Vassal, M. Delgado, P. Ribaud, M. Musset, T. Dorval, D. Machover, C. Jasmin, M. Hayat, L. Schwarzenberg, and G. Mathé)	29

7. Poor-Prognosis Acute Lymphoblastic Leukemias (M. Weil, C. Jacquillat, M. F. Auclerc, G. Schaison, C. Chastang, and J. Bernard)	36
8. Therapeutic Effectiveness of Neuraminidase- Treated Allogeneic Myeloblasts as Immunogen in Acute Myelocytic Leukemia (J. G. Bekesi and J. F. Holland)	42
9. Maintenance Chemoimmunotherapy of Nonlymphoblastic Acute Leukemias (R. Favre, G. Sebahoun, D. Bagarry-Liégey, C. Imbert, P. Ciardelli, J. A. Gastaut, G. Meyer, and Y. Carcassonne)	56
10. Possible Mechanisms of Immunotherapy Action in Acute Nonlymphatic Leukemia: Macrophage Production of Colony-Stimulating Activity (P. Reizenstein, B. Andersson, and M. Beran) ...	64
11. The Finnish Leukaemia Group: Levamisole in Maintenance Therapy of Acute Myeloid Leukemia in Adults (M. Lehtinen, P. Ahrenberg, A. Hänninen, E. Ikkala, R. Lahtinen, A. Levanto, I. Palva, A. Rajamäki, S. Rosengard, T. Ruutu, S. Sarna, O. Selroos, T. Timonen, E. Waris, C. Wasastjerna, J. Vilpo, and P. Vuopio)	70
12. Treatment of Acute Leukemia in Remission by Bone Marrow Transplantation (R. Storb)	73
13. Prevention of Blastic Crisis in Ph ¹ -Positive Chronic Myeloid Leukemia (J. C. Sharp)	78
14. A Southwest Oncology Group: Chemotherapy Versus Chemotherapy Plus Radiotherapy in Treatment of Stage III Hodgkin's Disease (P. N. Grozea, E. J. De Persio, C. A. Coltman Jr., C. J. Fabian, F. S. Morrison, E. A. Gehan, and S. E. Jones)	83
15. Maintenance Immunotherapy with BCG in Non-Hodgkin's Malignant Lymphomas: A Progress Report of a Randomized Trial (B. Hørni, M. Durand, H. Eghbali, G. Hørni-Simon, P. Richaud, and A. de Mascarel)	92

Contents	VII
III. Bone Tumors	98
16. Role of Lung Irradiation in the Adjuvant Treatment of Osteosarcoma (E. van der Schueren and K. Breur)	98
17. Adjuvant Interferon Treatment of Human Osteosarcoma (H. Strander, T. Aparisi, H. Blomgren, L. Å. Broström, K. Cantell, S. Einhorn, S. Ingimarsson, U. Nilsson, and G. Söderberg) .	103
18. A Strategic Adjuvant Therapy of Osteosarcoma (C. Jasmin)	108
19. Ewing's Sarcoma: Treatment with High-Dose Radiation and Adjuvant Chemotherapy (A. Goldman)	115
20. Adjuvant Chemotherapy in Ewing's Sarcoma Patients (M. Gasparini and F. Lombardi)	120
21. Early Results of Combined Modality Therapy of Patients with Ewing's Sarcoma (D. K. Hossfeld, S. Seeber, E. Siemers, C. G. Schmidt, and E. Scherer)	124
22. Ewing's Sarcoma: 5-Year Survival Under Adjuvant Chemotherapy (B. P. Le Mevel)	128
IV. Breast Carcinoma	134
23. Natural History of Breast Cancer (S. Gore, A. Langlands, S. Pocock, and G. Kerr)	134
24. Adjuvant Chemotherapy in Breast Cancer (R. Nissen-Meyer, K. Kjellgren, and B. Mansson)	142
25. Multimodal Therapy with CMF in Resectable Breast Cancer with Positive Axillary Nodes: The Milan Institute Experience (G. Bonadonna, P. Valagussa, A. Rossi, G. Tancini, C. Brambilla, S. Marchini, and U. Veronesi)	149
26. Follow-Up Results from a Randomized Trial for T ₃ and T ₄ Breast Cancer Patients: Previous BCG Immunotherapy Improves Response to Chemotherapy in the Relapse Patient (B. Serrou, H. Sancho-Garnier, P. Cappelaere, R. Plagne, R. Metz, M. Schneider, P. Chollet, N. Namer, H. Pujol, J. Gary-Bobo, G. Meyer, and G. Mathé)	157

27.	Adjuvant Treatment of Node-Positive Breast Cancer with Adriamycin-Cyclophosphamide with or Without Radiation Therapy: Interim Results of an Ongoing Clinical Trial (S. E. Jones, S. E. Salmon, H. Allen, G. F. Giordano, S. Davis, E. Chase, T. E. Moon, and R. S. Heusinkveld)	162
28.	A Randomized Trial of Postoperative Five-Versus Three-Drug Chemotherapy After Mastectomy: A Cancer and Leukemia Group B (CALGB) Study (R. Weiss, D. C. Tormey, F. Holland, V. E. Weinberg, G. Lesnick, M. Perloff, G. Falkson, and O. J. Glidewell)	170
29.	Adjuvant Chemoimmunotherapy with LMF Plus BCG in Node-Negative and Node-Positive Breast Cancer – Intermediate Report at 4 Years (H. J. Senn, R. Amgwerd, W. F. Jungi, R. Hochuli, J. Ammann, G. Engelhart, C. Heinz, A. Wick, F. Enderlin, G. Creux, B. Simon, R. Lanz, R. Bigler, and S. Seiler)	177
30.	Adjuvant Intermittent Chemoimmunotherapy for Primary Breast Cancer: A Prospective Study with Immunologic Follow-Up (M. Betzler, W. Schreml, M. Lang, H. P. Lohrmann, H. D. Flad, P. Schlag, C. Herfarth, and H. Heimpel)	185
31.	Short-Term and Long-Term Effects of Chemoimmunotherapy on Granulopoiesis: Adjuvant Therapy of Breast Cancer (H. P. Lohrmann, W. Schreml, and M. Lang)	192
32.	A New Adjuvant Treatment with Polyadenylic-Polyuridylic Acid in Operable Breast Cancer (F. Lacour, J. Lacour, A. Spira, M. Michelson, G. Delage, J. Y. Petit, and J. Viguiet)	200
V.	Lung Carcinoma	207
33.	Metastatic CNS Disease in Small Cell Carcinoma of the Bronchus: The Role of Radiotherapy and Chemotherapy (J. M. A. Whitehouse and C. J. Williams)	207
34.	Interim Results of EORTC Protocol 08742: Comparison, After Irradiation of Locally Advanced Squamous Cell Bronchial Carcinoma, of Abstention, Immunotherapy, Combination Chemotherapy or Chemoimmunotherapy (L. Israel, A. Depierre, and O. Dalesio)	214

35.	Immunologically Defined Prognostic Subgroups as Predictors of Response to BCG Immunotherapy (J. W. Reid, G. B. Cannon, E. Perlin, J. Blom, R. Connor, and R. B. Herberman)	219
36.	Intrapleural BCG Immunotherapy of Lung Cancer Patients (C. Maver, H. Kausel, L. Lininger, and M. McKneally)	227
37.	Specific Active Immunotherapy in Lung Cancer: The Induction of Long-Lasting Cellular Responses to Tumour-Associated Antigens (T. H. M. Stewart, A. C. Hollinshead, J. E. Harris, and S. Raman)	232
38.	Malnutrition in Lung Cancer: Incidence, Prognostic Implications, and Pathogenesis (D. L. Kisner)	240
39.	Follow-Up of a Randomized Trial for Oat Cell Carcinoma Evaluating the Efficacy of Peripheral Intravenous Nutrition (PIVN) as Adjunct Treatment (B. Serrou, D. Cupissol, R. Plagne, P. Boutin, P. Chollet, Y. Carcassonne, and F. B. Michel)	246
VI.	Melanoma	254
40.	Clinical Trials of Chemotherapy and Chemoimmunotherapy in Primary Malignant Melanoma (C. Jacquillat, P. Banzet, and J. Maral)	254
41.	Trial 6: Randomized Study of Prolonged Chemotherapy, Immunotherapy, and Chemoimmunotherapy as an Adjuvant to Surgery for Stage I and II Melanoma. A Progress Report (G. Beretta)	259
42.	Current Status of Melanoma Chemotherapy and Immunotherapy (B. M. Czarnetzki, E. Macher, H. Behrendt, and F. Lejeune)	264
VII.	Testicular Neoplasia	269
43.	Adjuvant Therapy of Testicular Carcinoma (C. G. Schmidt)	269

VIII. Gastrointestinal Neoplasms 277

44. Adjuvant 5-Fluorouracil and BCNU
Chemotherapy in Gastric Cancer: 3-Year Results
(P. Schlag, W. Schreml, W. Gaus, C. Herfarth,
M. M. Linder, W. Queisser, and M. Trede) 277
45. Adjuvant Chemotherapy in Colon and Gastric
Cancer
(J. S. Macdonald, D. G. Haller, and D. L. Kisner) 284
46. Chemotherapy of Metastatic Gastrointestinal
Cancers: Prospects for Future Adjuvant Systemic
Therapies
(D. L. Kisner and J. S. Macdonald) 291
47. Chemotherapy of Carcinomas of the Digestive
Tract
(C. Gisselbrecht, D. Belpomme, L. Mignot,
M. Marty, G. Mathé, and M. Boiron) 296

IX. Conclusions and Prospects 303

48. Clinical Trials on Adjuvant Therapies in Cancer:
Short-Term and Long-Term Results
(P. Valagussa and G. Bonadonna) 303
49. Long-Term Costs of Adjuvant Radiotherapy
(F. Volterrani and D. Sigurtà) 308
50. Long-Term Cost of Combined Radiotherapy and
Chemotherapy
(M. Weil, C. Jacquillat, G. Auclerc, P. F. Unger,
and J. Bernard) 312
51. Studies of Clonogenic Human Tumor Stem Cells
(S. E. Salmon) 317
52. Current Status of Clinical Trials of m-AMSA,
Dihydroxyanthracenedione, and
Deoxycoformycin
(J. S. Macdonald, S. Marsoni, S. Bruno, and
D. Poster) 323
53. Three New Agents for Immunotherapy Trials:
Azimexon, Bestatin, and Tuftsin
(G. Mathé, I. Florentin, M. Bruley-Rosset,
A. Goutner, and B. Serrou) 331
54. Emerging Immunologic Approaches to Treatment
of Neoplastic Diseases
(L. Olsson and G. Mathé) 334

55. Cellular Interactions Modulating Host Resistance to Tumours
(R. W. Baldwin, V. S. Byers, D. Hannant, J. A. Jones, M. V. Pimm, and M. R. Price) 338
56. Preliminary Clinical Results with Norgamen (Thioprolone) and Revercan (S-Amino-2-Thiazoline): The First Inducers of Reverse Transformation
(A. Brugarolas and M. Gosálvez) 346
57. Biologic Response Modifiers and Adjuvant Chemotherapy: Consideration of Selected Preclinical Investigations in Relation to Clinical Potential
(A. Goldin, M. A. Chirigos, J. S. Macdonald, A. Fefer, and E. Mihich) 351

I. General Considerations

*1. Metastatic Potential of Metastases, Tumor Cell Heterogeneity, and Therapeutic Implications**

F. Spreafico, A. Mantovani, R. Giavazzi, G. Conti, and A. Anaclerio

Istituto di Ricerche Farmacologiche 'Mario Negri',
Via Eritrea 62, I-20157 Milan, Italy

Summary

The metastasizing capacity of spontaneous metastases of several murine tumors of different histology, origin, and disseminative pattern was investigated to test the hypothesis that metastases originate from various subpopulations within the primary tumor. Overall, tumor cells from individual metastases did not show greater metastasizing capacity than the cells of the original tumor, although a degree of heterogeneity was seen. Differences in the immunologic profile among metastases of the same tumor were also observed. The possible therapeutic implications of these findings are discussed.

Introduction

Oncologists need not be reminded that the real targets of adjuvant chemotherapy are tumor metastases. Although it can easily be advanced that the formation of metastases is the root of clinical malignancy, our ignorance of metastasis formation, the final result of a complex series of events in which an array of host and tumor factors interact, is still substantial. Yet, to devise more effective and intelligent therapeutic strategies aimed at the prevention and/or treatment of metastatic disease, a more in-depth understanding is needed as to the pathogenesis of invasion, dissemination, and peripheral colonization, and of the properties of metastatic cells vis à vis those of the primary tumor.

The Metastatic Potential of Metastatic Cells

Studies from various groups have recently provided evidence that clones from primary murine neoplasms can differ markedly in various biologic characteristics including their capacity to form secondary tumors [5, 11]. Tumor cell lines could be obtained possessing increased metastasizing capacity or which were capable of homing

* This work was supported by PHS grant R01-CA-12764 from the NCI, USA, and by contract 78.0279.96 from Progetto Finalizzato Controllo Crescita Neoplastica, CNR, Rome, Italy

selectively at certain anatomic sites [1, 11, 14]. With this background, the contention has been advanced that the formation of secondary tumors is not the result of the random survival of cells which have disseminated from the primary tumor, but that they derive from the establishment and growth of a specialized subpopulation of cells preexisting within the primary tumor. These cells would be endowed with specific and still largely undefined properties allowing them to more effectively complete a highly complex and very selective process [4, 11]. With regard to the latter point, less than 0.1% neoplastic cells from a primary tumor which have reached the circulation may survive arrest in peripheral organs and, still less, establish and grow into an acutal metastasis. If proven true, the hypothesis of the existence of cell subpopulations with intrinsically greater metastasizing ability could obviously have important implications. It was, therefore, of interest to investigate the metastasizing capacity of cells from spontaneous experimental metastases. In fact, if metastatic cells are the survivors of a highly selective process as the hypothesis implies, it would be expected that metastatic cells are better equipped to undergo the demanding process of metastasization. In a first series of studies, individual pulmonary metastases of a murine fibrosarcoma (mFS6) were investigated for their capacity to spontaneously metastasize after one s.c. passage in syngeneic animals (protocol A) or immediately after their isolation from the lung (protocol B). Since results obtained with the two protocols were similar, the data from protocol A are shown. Details of experimental conditions can be found elsewhere [7]. Table 1 shows that although all cell lines had comparable growth rates, they were heterogenous in their metastasizing ability; some lines (M4 and M7) being more metastatic, others (M8 and M9) being less metastatic than the primary cells. The majority of cell lines were, however, as metastatic as the primary mFS6 tumor. Since the B16 melanoma was the tumor first employed to show that clones from the primary tumor can markedly differ in their capacity to give artificial metastases upon i.v. cell inoculation [3], it was of interest to examine the metastatic potential of single spontaneous metastases. Following protocol A, it was found that nine of ten lines from individual pulmonary nodules were as metastatic as the primary tumor in terms of both number of lung lesions and their weight, whereas line B8 had a significantly reduced metastatic capacity (Table 1).

A similar pattern was seen when another murine neoplasm of still different histologic origin and metastases from organs other than the lung were examined. Upon i.m., s.c., or i.p. transplantation the M5076/73 ovarian carcinoma gives secondary tumors only in subdiaphragmatic organs, lung nodules not being observed after i.v. injection [10]. Also, in this condition, the majority of cells lines from individual metastases were not hypermetastatic compared to the primary tumor (Table 2), and equivalent results were seen when protocol B was adopted. This confirms, in this model, the comparability of the two experimental approaches previously observed for the mFS6 tumor. The representative results of Table 2 additionally show that, in the majority, cell lines obtained from single metastasis which originated in a given organ did not appear to preferentially show secondary localizations in organ where they had originally settled. Again, comparable results as regards both the metastatic potential of spontaneous metastases, as well as the general absence of a preferential localization in the site of origin, were seen when the colon 26 carcinoma was studied. Since tumors of relatively long transplantation history had been used for our studies, it was of interest to also investigate a neoplasm of recent origin. For this purpose a second passage, which spontaneously metastasized, methylcholanthrene-induced sarcoma of C57B1/6 mice (MN/MCA 1) was used. Here also a degree of heterogeneity in metastatic potential

Table 1. Spontaneous metastasizing capacity of tumor cell lines derived from individual lung secondary tumors of the mFS6 sarcoma and B16 melanoma

Tumor line	MST (range) ^a	Mice with metastases/total	Metastases number (± SE) ^b	Metastases weight (mg ± SE) ^b
Primary mFS6 ^c	33 (25–50)	17/32	3.3 ± 0.3	18.2 ± 5.4
Cell line from metastasis				
no. M1	38 (25–49)	4/8	5.2 ± 3.2	50.1 ± 0.9
M2	32 (28–55)	6/15	3.2 ± 1.2	7.8 ± 7.0
M3	36 (25–48)	10/16	8.7 ± 3.0	48.9 ± 33.2
M4	36 (30–49)	13/14 ^c	16.7 ± 3.6 ^c	122.5 ± 38.5 ^c
M5	33 (25–41)	10/15	8.7 ± 1.8	45.7 ± 20.0
M6	31 (27–42)	10/15	7.8 ± 2.9	11.3 ± 4.0
M7	44 (33–52)	15/15 ^c	13.8 ± 2.6 ^c	170.2 ± 12.7 ^c
M8	35 (26–27)	1/16 ^c	1.0	0.5
M9	38 (30–51)	0/15 ^c	—	—
Primary B16 ^d	28 (24–33)	11/12	7.11 ± 2.2	4.0 ± 1.1
Cell line from metastasis				
no. B1	28 (24–35)	4/7	7.5 ± 2.5	14.3 ± 3.8
B2	30 (28–37)	4/7	1.7 ± 0.4	2.6 ± 1.7
B3	32 (28–36)	2/6	4.0 ± 1.0	5.7 ± 1.5
B4	31	6/8	8.1 ± 3.0	7.3 ± 3.3
B5	27 (23–32)	2/6	2.5 ± 0.5	1.3 ± 0.9
B6	27 (24–38)	6/9	8.8 ± 3.3	5.8 ± 1.7
B7	32 (29–42)	5/8	3.2 ± 1.1	1.6 ± 0.1
B8	28 (24–37)	1/7 ^c	10 ± 0	8.8 ± 0
B9	32 (23–37)	4/5	11.5 ± 4.6	8.7 ± 2.9
B10	35 (26–42)	7/8	10.3 ± 3.9	9.9 ± 3.1

^a Median survival time in days with range
^b Number and weight of lung metastases/mouse
^c Tumor cells (10⁴) injected i.m. in C57Bl/6 mice. Metastases counted at death
^d Tumor cells (10⁵) injected i.m. in C57Bl/6 mice. Metastases counted at death
^e Compared to primary tumor, *P* < 0.01

was seen (Table 3), since the L2 metastatic line was hypermetastatic and lines L5 and L7 were hypometastatic (indeed, not metastasizing) compared to the primary tumor. However, again the majority (10 of 14) of cell lines from metastases produced metastases comparable to the primary in terms of incidence of animals with secondaries, as well as number and weight of lesions per lung. From the data presented and obtained using a series of murine tumors of different histology, pattern of dissemination, and transplantation history, it appears that cells from spontaneous metastases do not generally possess an enhanced metastasizing capacity in respect to the primary tumor from which they had originated. Although a heterogeneity is clearly recognizable both among metastases and compared to the primary with both hyper- and hypometastatic cells, our findings do not appear to support the general contention that metastases arise from the progeny of cells with